NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics launched RaDaR ST, a circulating tumor DNA (ctDNA) assay for molecular residual disease (MRD) across multiple solid tumor types. The test expands MRD monitoring options for post-treatment recurrence detection and clinical decision support.
Why it mattersCtDNA MRD testing across multiple solid tumors enables earlier recurrence detection.
Entities Mentioned
NeoGenomics